Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 7373196, 8 pages
Research Article

Passive Immunoprophylaxis for the Protection of the Mother and Her Baby: Insights from In Vivo Models of Antibody Transport

1Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, CBER/FDA, Plasma Derivatives Branch, Silver Spring, MD, USA
2Division of Clinical Evaluation and Pharmacology/Toxicology, Office of Tissues and Advanced Therapies, CBER/FDA, Silver Spring, MD, USA

Correspondence should be addressed to Evi B. Struble; vog.shh.adf@elburts.ive

Received 26 August 2016; Accepted 21 November 2016; Published 11 January 2017

Academic Editor: Roberta A. Diotti

Copyright © 2017 Yanqun Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

The time course of human IgG concentration following intravenous administration of HepaGam® at two doses to pregnant guinea pigs 2-6 days before parturition is shown in Figure 1S. Both the average and normalized (% Cmax) IgG levels are lower in pregnant guinea pigs compared to non-pregnant controls at same time-points. Table 1S shows the individual values for maternal and fetal concentration five days following HepaGam® administration to pregnant guinea pigs at different gestation ages.

  1. Supplementary Material